BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27824245)

  • 21. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
    Stravitz RT; Shiffman ML; Sanyal AJ; Luketic VA; Sterling RK; Heuman DM; Ashworth A; Mills AS; Contos M; Cotterell AH; Maluf D; Posner MP; Fisher RA
    Liver Transpl; 2004 Jul; 10(7):850-8. PubMed ID: 15237368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant.
    Punzalan CS; Barry C; Zacharias I; Rodrigues J; Mehta S; Bozorgzadeh A; Barnard GF
    Clin Transplant; 2015 Dec; 29(12):1105-11. PubMed ID: 26358816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus and liver transplantation: where do we stand?
    Burra P; De Martin E; Zanetto A; Senzolo M; Russo FP; Zanus G; Fagiuoli S
    Transpl Int; 2016 Feb; 29(2):135-52. PubMed ID: 26199060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
    Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
    Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Direct-acting antivirals ability to clear intestinal HCV-RNA in liver transplant patients.
    Pietrosi G; Russelli G; Barbera F; Curcio G; Tuzzolino F; Gallo A; Volpes R; Vizzini G; Conaldi PG
    Transpl Infect Dis; 2020 Oct; 22(5):e13345. PubMed ID: 32495971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bridging all oral DAA therapy from wait time to post-liver transplant to improve HCV eradication?
    Donato MF; Monico S; Malinverno F; Aghemo A; Maggioni M; Reggiani P; Colombo M
    Liver Int; 2015 Jan; 35(1):1-4. PubMed ID: 25074044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New modalities in the treatment of HCV in pre and post - transplantation setting.
    Araz F; Durand CM; Gürakar A
    Turk J Gastroenterol; 2015 May; 26(3):204-13. PubMed ID: 26006192
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.
    Firpi RJ; Abdelmalek MF; Soldevila-Pico C; Reed A; Hemming A; Howard R; Van Der Werf W; Lauwers G; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2002 Nov; 8(11):1000-6. PubMed ID: 12424712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preemptive antiviral treatment for hepatitis C virus after living donor liver transplantation.
    Sugawara Y; Tamura S; Yamashiki N; Kaneko J; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N
    Transplant Proc; 2012 Apr; 44(3):791-3. PubMed ID: 22483497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current management and perspectives for HCV recurrence after liver transplantation.
    Coilly A; Roche B; Samuel D
    Liver Int; 2013 Feb; 33 Suppl 1():56-62. PubMed ID: 23286847
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Direct-acting antiviral drugs against hepatitis C virus in renal transplant recipients: Is it the dawn of an interferon-free Era?
    Rangaswamy D; Nagaraju SP; Attur RP
    Saudi J Kidney Dis Transpl; 2017; 28(5):1169-1174. PubMed ID: 28937081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interferon-Free Sofosbuvir-Based Anti-HCV Therapy After Liver Transplantation.
    Seifert LL; Vorona E; Bester C; Stahl M; Hüsing A; Beckebaum S; Kabar I; Heinzow H; Schmidt HH
    Ann Transplant; 2015 Sep; 20():561-8. PubMed ID: 26391423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin.
    Gopal DV; Rabkin JM; Berk BS; Corless CL; Chou S; Olyaei A; Orloff SL; Rosen HR
    Liver Transpl; 2001 Mar; 7(3):181-90. PubMed ID: 11244158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
    Ueda Y; Uemoto S
    Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sofosbuvir and ribavirin before liver re-transplantation for graft failure due to recurrent hepatitis C: a case report.
    Vionnet J; Pascual M; Chtioui H; Giostra E; Majno PE; Decosterd LA; Moradpour D
    BMC Gastroenterol; 2015 Mar; 15():38. PubMed ID: 25887762
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.